Account Info
Log Out
English
Back
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh Refresh
Loading
History record delete
    Quotes All >
      News All >
        Log in to access Online Inquiry
        Watchlist
        Loading...
        HK Stock MarketDetailed Quotes
        01244 3D MEDICINES Watchlist
        90.750 +5.750+6.76%
        Trading 06/09 14:46 CST
        91.700High84.900Low458.50KVolume

        Company Profile

        Symbol
        01244
        Company Name
        3D MEDICINES
        ISIN
        KYG8872R1011
        Listing Date
        12/15/2022
        Founded
        01/30/2018
        Registration
        Cayman Islands
        Chairman
        Zhaolong Gong
        Secretary
        Fang\lijingyi Xia
        Audit Institution
        Ernst & Young
        Company Category
        Overseas registration of Mainland Individuals control
        Registered Office
        Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands
        Head Office and Principal Place of Business
        14th Floor, Golden Dragon Centre, 188 Des Voeux Road Central, Hong Kong
        Fiscal Year Ends
        12-31
        Employees
        245
        Market
        Hong Kong motherboard
        Phone
        (86)(010)67888635
        Email
        ir@3d-medicines.com
        Business
        3D Tumor Biotechnology Shanghai Co Ltd is a Chinese company mainly engaged in the development of commercial oncology products and drug candidates. The company's main product pipeline includes immuno-oncology monotherapy, drug candidates with mechanisms of action suitable for in-line combinations, and pain management assets. The company's core product is envolizumab, an anti-PD-L1 drug injected subcutaneously. The company also has several clinical-stage drug candidates, including the peptide cancer vaccine 3D189, the GAS6 decoy receptor 3D229, and the fibroblast growth factor receptor (FGFR) 3D185. The company mainly operates in the domestic market.
        Description
        3D Medication Inc. (www.3d-medicines.com) is a pharmaceutical company focusing on the field of cancer treatment that has entered the commercialization stage. Adhering to the vision of “helping cancer patients live longer and better”, combined with the future trend of chronic cancer treatment, it develops next-generation oncology drugs for cancer patients around the world. The company's product line includes 12 innovative drug candidates with clinical value and differentiated or global leadership. Of these, 8 have entered clinical development or commercialization, including the world's first new PD-L1 monomonial antibody drug, which has been conditionally approved by the China Drug Administration to be marketed in China; the introduction of the first-in-class polypeptide tumor vaccine 3D189 and the Gas6/AXL inhibitor 3D229 has been approved by the FDA for global phase III MRCT clinical research; the self-developed multi-target kinase inhibitor 3D011 has also entered clinical trials In the development phase, the other 4 products targeting FGFR123\ EP4\ COX2\ CD47 respectively have also entered the clinical stage at home and abroad. Preclinical varieties also include the internationally leading dual antibody CD3xPD-L1. The company currently has an international team of more than 250 people in the development, production and commercialization of new drugs to explore better treatments for cancer patients around the world.

        Company Executives

        No Data

        Paper Trade Start
        Symbol
        Direction
        Buy
        Sell
        Types
        LMT Order
        Price
        QTY
        Amount
        --